Can a drug calm uncontrollable movements? new trial tests tetrabenazine

NCT ID NCT01543321

Completed Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether tetrabenazine (Xenazine) can reduce involuntary movements in people with tardive dyskinesia, a condition caused by long-term use of antipsychotic medications. Fifty-four adults with persistent symptoms were randomly assigned to receive either tetrabenazine or a placebo for 10 weeks. The study measured changes in movement severity using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tetrabenazine (Xenazine)
What this could lead to: If successful, this could provide a proven treatment option to reduce involuntary movements in people with tardive dyskinesia, improving their quality of life.
What could go wrong: This is a small Phase 3 trial with only 54 participants, so results may not apply to everyone. Tetrabenazine can cause side effects like drowsiness or parkinsonism, and the benefit may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

movement disorder tardive dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TARDIVE DYSKINESIA

Contacts and locations

Locations

AP-HM Hopital de la Timone

Marseille, 13385, France
CH Aix en Provence

Aix-en-Provence, 13100, France
CH des Charpennes

Lyon, 69100, France
CHRU Lille

Lille, 59037, France
CHRU de Nimes

Nîmes, 30900, France
CHU Amiens

Amiens, Picardie, 80000, France
CHU Bordeaux

Bordeaux, 33076, France
CHU Caen

Caen, 14033, France
CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France
CHU Limoges

Limoges, 87042, France
CHU Montpellier

Montpellier, 34295, France
CHU Nantes

Nantes, 44093, France
CHU Nice

Nice, 06002, France
CHU Poitiers

Poitiers, 86021, France
CHU Rouen

Rouen, 76031, France
CHU Saint Antoine

Paris, 75012, France
CHU Strasbourg

Strasbourg, 67091, France
CHU Toulouse

Toulouse, 31059, France
CHU de Rennes

Rennes, 35033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.